Work

Fanconi Syndrome After a Single Exposure to Intravenous Zoledronic Acid

Year: 2026

Type: article

Abstract: Bisphosphonates are commonly used to reduce fracture risk in patients with osteoporosis, in those with malignant metastatic bone disease and for treatment of malignant hypercalcaemia. We present the case of a woman in her 80s admitted with recurrent falls who developed Fanconi syndrome after a single dose of intravenous Zoledronic acid despite normal renal function. In this report, we review the literature exploring nephrotoxicity secondary to Zoledronic acid use, recognizing that there are other reported cases of Fanconi syndrome; however, all in patients with malignancy rather than for osteoporosis. We also present one of the first cases of Fanconi syndrome after just a single exposure to Zoledronic acid in a patient who had normal preceding renal function. This highlights the need to be aware of the possibility of significant nephrotoxicity after a single exposure to Zoledronic acid even without the recognized risk factors of chronic or acute kidney disease.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.71868

Authors: Rita Deb, Muhammad Elboghdady, Alvin Shrestha

Institutions: St George’s University Hospitals NHS Foundation Trust, Imperial College London

Language: English

Topic: Bone health and treatments

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820